+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients



Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients



Pediatric Transplantation 5(4): 297-301



Rejection remains a major threat in pediatric renal transplantation (Tx), causing graft failure and increased exposure to drugs. The new chimeric antibody, basiliximab, directed against the alpha-chain of the interleukin-2 receptor (IL-2R), has been shown to be effective in preventing rejection episodes in adult renal transplant recipients. In our single-center experience from Essen, Germany, we evaluated prospectively the efficacy and tolerability of basiliximab, in combination with cyclosporin A (CsA) and prednisone, in 38 unselected pediatric patients. Mean patient age at Tx was 10.1 yr. Twenty-eight children received a cadaveric organ and 10 children received living-related donor grafts. The 1-yr patient survival rate was 100% and the 1-yr graft survival rate was 95% (36/38 patients). No graft was lost as a result of immunological factors, and single rejection episodes were observed in eight patients (21%). Two of these rejections were steroid-resistant and responded to tacrolimus rescue therapy. The rate of infections was not enhanced; overt cytomegalovirus (CMV) disease was observed in two patients only. Malignancies have not been seen to date. The blockade of the alpha-chain of the IL-2R lasted for up to 6 weeks. We conclude that the addition of basiliximab to standard immunosuppression in pediatric renal transplant recipients is well tolerated and results in a low incidence of rejection. The simple mode of application and the lack of side-effects make basiliximab an especially useful adjunct in pediatric patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045926897

Download citation: RISBibTeXText

PMID: 11472610

DOI: 10.1034/j.1399-3046.2001.005004297.x


Related references

Duration of interleukin-2 receptor saturation by basiliximab in pediatric renal transplant recipients. Pediatric Nephrology 13(7): C91, 1999

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 74(7): 961-966, 2002

Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients. Transplantation Proceedings 32(8): 2757-2759, 2000

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplantation Proceedings 33(5): 2767-2769, 2001

Interleukin-2-receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplant recipients. Journal of Heart and Lung Transplantation 20(2): 221-222, 2001

Influence of basiliximab and on recipients' interleukin-2 and soluble interleukin-2 receptor after renal transplantation. Zhongguo Xinyao yu Linchuang Zazhi 24(1): 50-53, 2005

Basiliximab induced non-cardiogenic pulmonary edema in two pediatric renal transplant recipients. Pediatric Nephrology 24(11): 2261-2265, 2009

A comparison of early graft function in pediatric renal transplant recipients treated with basiliximab. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 739A, 1999

Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 86(9): 1234-1240, 2008

The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. Bmc Nephrology 19(1): 263, 2018

Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients. Transplantation Proceedings 33(7-8): 3172-3173, 2001

Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids. Transplantation Proceedings 37(2): 672-674, 2005

Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. American Journal of Transplantation 8(5): 984-989, 2008

IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients. Transplantation Proceedings 35(1): 195, 2003

Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transplantation 8(2): 123-131, 2002